Navigation Links
Ceregene Reports Data From Parkinson's Disease Phase 2b Study
Date:4/19/2013

#160;                                                       

Ceregene established a leadership position in the fields of gene therapy and neurotrophic factors for the treatment of neurodegenerative diseases. A total of over 100 patients have been safely dosed in two clinical programs: CERE-120 (AAV-NRTN) for Parkinson's disease and CERE-110 (AAV-NGF) for Alzheimer's disease. A randomized, controlled Phase 2 study of CERE-110 for Alzheimer's is continuing. It is fully enrolled and financially supported in large part by a grant from the NIH, with top line data expected by late 2014. In addition to the Parkinson's and Alzheimer's programs, Ceregene has conducted extensive preclinical work with CERE-120 for Huntington's disease, as well as another gene therapy/neurotrophic factor product (AAV-NT4) for blinding ocular diseases (such as Retinitis Pigmentosa, macular degeneration, diabetic retinopathy and glaucoma) and yet another (AAV-IGF1) for Lou Gehrig 's disease (ALS). Ceregene is currently looking at strategic alternatives to advance its AAV gene therapy platform.

About CERE-120 and its Application to Treating Parkinson's Disease
CERE-120 is composed of a harmless adeno-associated virus (AAV) vector carrying the gene for neurturin, a naturally occurring protein known to repair damaged and dying dopamine-secreting neurons, keeping them alive and restoring function.  Neurturin is a member of the same protein family as glial cell line-derived neurotrophic factor (GDNF).  The two molecules have similar pharmacological properties and both have been shown to benefit the midbrain dopamine neurons that degenera
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
2. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
3. Interleukin Genetics Reports Third Quarter 2011 Financial Results
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
6. Pharmasset Reports Fiscal Year End 2011 Financial Results
7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
8. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
9. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
10. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
11. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 EquitiesIQ, a leading informational research ... Alliqua is an emerging biomedical company acquiring, developing, manufacturing, ... market. , Free report download: http://equitiesiq.com/reports/alliqua/ , ... management team and Board, which launched the company’s new ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 In recent ... motives and methods in product development and promotion has ... industry. This mistrust, fueled by concerns about the insidious ... by reports of spectacular fines to the world’s biggest ...
(Date:1/14/2014)... January 13, 2014 Bob Hainsey, a ... than 20 years in the industry, has joined ... Hainsey will serve as the society’s Science and Technology ... join SPIE as our Technology Strategist, further strengthening the ...
(Date:1/14/2014)... Park, NC (PRWEB) January 14, 2014 ... focusing on ultra-sensitive POC diagnostic platforms and novel disease specific ... first round of financing netting a total of $690,000. The ... equity capital in the company. This group of private investors ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... Yongye Biotechnology,International, Inc. (OTC Bulletin Board: YGYB) ("Yongye" ... of nutrients for plants and,animals in the People,s ... a conference call at 8:00 a.m. Eastern Time ... the quarter ended June 30, 2008., To ...
... Massachusetts, August 13, Shire Limited (LSE: SHP, NASDAQ: ... since July,3, 2008 it has acquired 81% of ... indirect subsidiary Shire Deutschland Investments GmbH (formerly Maia,Elfte ... respect of the remaining outstanding shares in Jerini., ...
... Finn, Jr.,C.P.A. ("Finn"), Assignee of the assets of Spherics, ... all pharmaceutical,intellectual property will be sold at a sealed ... pieces of intellectual property for sale is its lead,product, ... currently has,more than $2 billion in sales despite twice ...
Cached Biology Technology:Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results 2Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document 2Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document 3
(Date:7/9/2014)... selection for traits that are attractive to the opposite ... to mate, the tail of male peacocks being an ... Riverside have now found that sexual selection and "placentation" ... Describing the life histories of more than 150 species ... that species with placentas tend to have males that ...
(Date:7/9/2014)... A crucial piece of the puzzle behind nature,s ... that could help advance the development of artificial ... been provided by an international collaboration of scientists ... Laboratory (Berkeley Lab) and the SLAC National Accelerator ... Light Source (LCLS), the world,s most powerful x-ray ...
(Date:7/9/2014)... Researchers studying critically ill children with traumatic injuries ... patients are likely to develop a hospital-acquired infection. ... Hospital and published online in June in the ... larger efforts that could lead to the clinical ... to prevent or reverse immune system damage following ...
Breaking Biology News(10 mins):Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4Postcards from the photosynthetic edge 2Postcards from the photosynthetic edge 3Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
... 19, 2009Scientists say they are forging ahead in developing ... renewable while having a minimal impact on the environment, ... A consensus is emerging that no one technology will ... novel methodologies will contribute to meeting biofuel needs, according ...
... Swiss Institute of Bioinformatics today announced the winners of the ... Award at the 7th annual [BC]2 Basel Computational Biology Conference. ... The winner of the 2009 SIB Young Bioinformatician Award is ... the past four years with the SIB in the Bioinformatics ...
... of Cordell Bank National Marine Sanctuary indicates that the ... is fair to good, but identifies several emerging threats ... as marine debris, ocean acidification and invasive species have ... said Dan Howard, sanctuary superintendent. "This report provides a ...
Cached Biology News:The SIB recognizes the next generation of bioinformaticians 2The SIB recognizes the next generation of bioinformaticians 3NOAA report finds threats to California's Cordell Bank Marine Sanctuary 2